Dr. Robert Evan Reiter, MD

Dr. Reiter practices at Peter Morton UCLA Medical Building in Los Angeles, California.

Dr. Reiter's NPI, 1346269297, was assigned on July 19, 2006. Dr. Reiter graduated from Stanford University School Of Medicine in 1988. Dr. Reiter's California license number on file is G67515.

Dr. Reiter's primary practice is Peter Morton UCLA Medical Building, at 200 Medical Plz, Los Angeles, CA 90024 in Los Angeles County. The practice phone is (310) 794-9206.

Dr. Reiter's primary practice is Peter Morton UCLA Medical Building in Los Angeles, California. Dr. Reiter is also affiliated with Ronald Reagan UCLA Medical Center. The medical group on file is UCLA Urology. Dmand AI also links Dr. Reiter to 1 more hospital and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Reiter practices, 3 sites in all. Vendor and product names are available with a free account.

Urology is Dr. Reiter's primary specialty in the NPI Registry, under taxonomy code 208800000X. Dr. Reiter is board certified in urology by the American Board of Urology. Dr. Reiter has a license on file in California.

Dmand AI lists enlarged prostate, enlarged prostate transurethral surgery (TURP), erectile dysfunction, prostate cancer, prostate surgery, urinary endoscopy and UTI among the conditions Dr. Reiter treats.

CMS data shows 587 Medicare services from Dr. Reiter across 12 procedure codes in 2024, for 356 Medicare patients. Medicare paid $91,706 for them.

CMS counts 356 Medicare patients who saw Dr. Reiter in 2024. The largest group is 65 to 74, with 216 patients. 75% of them have high cholesterol, and 73% have cancer. 8% are also on Medicaid. Their average risk score is 0.92, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Reiter's median patient age at 68, with 0% women.

In 2024, Dr. Reiter wrote 148 Medicare Part D claims for 70 patients. 85% of them were for generic drugs. CMS names the drug for 103 of them, across 4 drugs with 11 or more claims each, at $13,072 in total drug cost. In 2023, CMS named 72 claims across 4 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 89 out of 100 for Dr. Reiter for performance year 2024, reported as part of a group. Dr. Reiter accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Reiter as offering telehealth. CMS counts 24 procedures of prostate resection by Dr. Reiter, more than 86% of the clinicians it reports for that procedure.

Dmand AI links 79 papers to Dr. Reiter, published from 2011 to 2025. 2018 was the busiest year, with 9. The most frequent topics are Prostatic Neoplasms, Prostatectomy and Prostatic Neoplasms, Castration-Resistant. Dr. Reiter has published most often in Eur Urol. Dr. Reiter's most frequent co-authors are Steven S. Raman, MD, Matthew B. Rettig, MD and Johannes Czernin, MD.

Dmand AI links Dr. Reiter to 2 clinical trials. Conditions studied include Prostatic Neoplasms and Prostatic Diseases.

CMS Open Payments shows 214 general payments to Dr. Reiter from 23 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 70% of the total. Janssen Pharmaceuticals, Inc paid the most, $119,158.

Dmand AI lists 2 awards for Dr. Reiter, most recently Super Doc in 2004.

Dr. Reiter graduated from Stanford University School Of Medicine in 1988.

Dr. Reiter is in network with 14 carriers, including Aetna, Blue Cross Blue Shield of Michigan and United Healthcare. Medicare plans come from the most carriers, 8. Check the plan with the practice before a visit.